Citadel Advisors
XBIT icon

Citadel Advisors’s XBiotech XBIT Stock Holding History

Citadel Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,800
Closed -$50.6K – 15710
2024
Q4 		$50.6K Buy
+12,800
New +$87.2K ﹤0.01% 12378
2024
Q3 		– Sell
-4,600
Closed -$23.6K – 15380
2024
Q2 		$23.6K Buy
4,600
+2,900
+171% +$22.4K ﹤0.01% 12492
2024
Q1 		$13.8K Buy
1,700
+1,500
+750% +$8.6K ﹤0.01% 13274
2023
Q4 		$800 Sell
200
-5,200
-96% -$20.7K ﹤0.01% 13938
2023
Q3 		$22.2K Buy
5,400
+200
+4% +$1K ﹤0.01% 12540
2023
Q2 		$30.9K Sell
5,200
-5,600
-52% -$25.3K ﹤0.01% 12323
2023
Q1 		$37.3K Buy
+10,800
New +$40.2K ﹤0.01% 12509
2021
Q4 		– Sell
-12,400
Closed -$161K – 14882
2021
Q3 		$161K Sell
12,400
-24,300
-66% -$387K ﹤0.01% 12280
2021
Q2 		$608K Sell
36,700
-23,600
-39% -$400K ﹤0.01% 9586
2021
Q1 		$1.03M Buy
60,300
+2,000
+3% +$37.3K ﹤0.01% 8027
2020
Q4 		$912K Buy
+58,300
New +$1.07M ﹤0.01% 6992
2018
Q1 		– Sell
-15,600
Closed -$61K – 8858
2017
Q4 		$61K Sell
15,600
-9,000
-37% -$37.9K ﹤0.01% 7571
2017
Q3 		$108K Sell
24,600
-6,400
-21% -$30.2K ﹤0.01% 7008
2017
Q2 		$146K Buy
+31,000
New +$297K ﹤0.01% 6762

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's XBIT Position: Q4 2025 in Review

Citadel Advisors sold out of XBiotech (XBIT) in Q4 2025, closing a stake of 42,816 shares — an estimated $106K sold.

Citadel Advisors first reported a position in XBIT in Q2 2017 and held it in 17 quarters. The position peaked at $619K in Q3 2021. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2025.

  • Citadel Advisors reported no remaining XBiotech position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 42,816 XBiotech shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in XBiotech in Q2 2017 and held it in 17 quarters.
  • Citadel Advisors's XBiotech position peaked at $619K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held XBiotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.